Purpose: We studied the clinical picture, sensitivity of the biochemic
al tests and imaging studies, pathological findings, surgical results
and followup of patients with pheochromocytoma. Materials and Methods:
The records of 50 patients with pheochromocytoma were identified. Hyp
eradrenergic symptoms and signs; urinary dopamine, epinephrine, norepi
nephrine and vanillylmandelic acid levels; serum dopamine, epinephrine
and norepinephrine levels; ultrasonography; computerized tomography;
magnetic resonance imaging and (131)iodine-metaiodobenzylguanidine ima
ges were analyzed. The size, weight and malignancy of the tumors, as w
ell as the operative mortality, survival rate and clinical condition o
f the patients were also studied. Results: The hyperadrenergic syndrom
e alone was found in 90% of the patients, Cushing's syndrome alone in
2%, both syndromes in 4%, a palpable abdominal tumor only in 2% and in
cidental tumors in 2%. The sensitivities of the urinary evaluation in
the diagnosis were metanephrines 97%, vanillylmandelic acid 90%, epine
phrine 64%, norepinephrine 93% and dopamine 66%. For serum assessment
the sensitivities were epinephrine 67%, norepinephrine 93% and dopamin
e 63%. The sensitivities of the localization examinations were 89, 94,
100 and 88% for ultrasonography, computerized tomography, magnetic re
sonance imaging and I-131-metaiodobenzylquanidine, respectively. There
was only 1 operative death. Of the patients with benign tumors 88% we
re cured and 12% remained hypertensive with no clinical or biochemical
evidence of a hyperadrenergic profile. Of the 8 patients with maligna
nt pheochromocytoma 1 was lost to followup and 3 died of widespread di
sease (1 without surgery and at 2, 24 and 78 months postoperatively).
Of the 4 living patients 3 had no evidence of disease and 1 was well,
although with pulmonary metastases.